B. Randazzo

5.0k total citations · 2 hit papers
71 papers, 3.9k citations indexed

About

B. Randazzo is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, B. Randazzo has authored 71 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Immunology, 18 papers in Dermatology and 12 papers in Physiology. Recurrent topics in B. Randazzo's work include Psoriasis: Treatment and Pathogenesis (30 papers), Dermatology and Skin Diseases (18 papers) and Asthma and respiratory diseases (10 papers). B. Randazzo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (30 papers), Dermatology and Skin Diseases (18 papers) and Asthma and respiratory diseases (10 papers). B. Randazzo collaborates with scholars based in United States, Canada and United Kingdom. B. Randazzo's co-authors include Yasmine Wasfi, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt, Michael Song, Kristian Reich, C.E.M. Griffiths, Kenneth B. Gordon, Alexa B. Kimball and Kim Papp and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

B. Randazzo

68 papers receiving 3.8k citations

Hit Papers

Efficacy and safety of gu... 2017 2026 2020 2023 2017 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
    2017 637 citations Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology profile →
  2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
    2017 537 citations Kristian Reich, April W. Armstrong et al. Journal of the American Academy of Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
B. Randazzo 2.7k 1.7k 713 565 558 71 3.9k
Carrie Brodmerkel 1.9k 0.7× 891 0.5× 623 0.9× 867 1.5× 409 0.7× 58 3.4k
Newman Yeilding 4.6k 1.7× 2.3k 1.4× 783 1.1× 997 1.8× 404 0.7× 34 5.7k
Lisa T. Dooley 5.4k 2.0× 2.9k 1.7× 812 1.1× 1.3k 2.3× 417 0.7× 15 6.1k
Marieke M.B. Seyger 1.7k 0.6× 1.3k 0.8× 335 0.5× 396 0.7× 183 0.3× 129 2.8k
Jörg C. Prinz 3.2k 1.2× 1.8k 1.0× 722 1.0× 544 1.0× 119 0.2× 64 4.0k
Edward W. Cowen 852 0.3× 602 0.4× 387 0.5× 389 0.7× 351 0.6× 155 3.2k
Mary Ann Mascelli 1.8k 0.6× 299 0.2× 507 0.7× 509 0.9× 337 0.6× 64 4.1k
Bernard S. Goffe 2.4k 0.9× 940 0.6× 246 0.3× 1.4k 2.4× 124 0.2× 23 3.3k
C. Leonardi 1.6k 0.6× 969 0.6× 253 0.4× 344 0.6× 153 0.3× 57 2.1k
Martine Bagot 1.8k 0.7× 2.4k 1.4× 329 0.5× 630 1.1× 137 0.2× 183 4.9k

Countries citing papers authored by B. Randazzo

Since Specialization
Citations

This map shows the geographic impact of B. Randazzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Randazzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Randazzo more than expected).

Fields of papers citing papers by B. Randazzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Randazzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Randazzo. The network helps show where B. Randazzo may publish in the future.

Co-authorship network of co-authors of B. Randazzo

This figure shows the co-authorship network connecting the top 25 collaborators of B. Randazzo. A scholar is included among the top collaborators of B. Randazzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Randazzo. B. Randazzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Silverberg, Jonathan I., Paul F. Lizzul, Jocelyne Papacharalambous, et al.. (2023). 89 A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 143(11). S347–S347. 1 indexed citations
2.
Blauvelt, Andrew, April W. Armstrong, Richard G. Langley, et al.. (2021). Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment. 33(4). 2317–2324. 21 indexed citations
3.
Langley, Richard G., Petr Arenberger, Susan Flavin, et al.. (2020). 15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study. Journal of the American Academy of Dermatology. 83(6). AB34–AB34. 3 indexed citations
4.
Reich, Kristian, April W. Armstrong, Richard G. Langley, et al.. (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet. 394(10201). 831–839. 259 indexed citations
5.
Armstrong, April W., Peter Foley, Yasmine Wasfi, et al.. (2018). LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2. 98. 3 indexed citations
6.
Blauvelt, Andrew, Kim Papp, C.E.M. Griffiths, et al.. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 76(3). 405–417. 637 indexed citations breakdown →
7.
Hu, Chuanpu, B. Randazzo, Amarnath Sharma, & Honghui Zhou. (2017). Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. Journal of Pharmacokinetics and Pharmacodynamics. 44(5). 437–448. 19 indexed citations
8.
Reich, Kristian, April W. Armstrong, Peter Foley, et al.. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology. 76(3). 418–431. 537 indexed citations breakdown →
9.
Li, Katherine, Chaohua Huang, B. Randazzo, et al.. (2016). HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program. Journal of Investigative Dermatology. 136(12). 2364–2371. 41 indexed citations
10.
Gordon, Kenneth B., Kristina Callis Duffin, Robert Bissonnette, et al.. (2015). A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. New England Journal of Medicine. 373(2). 136–144. 242 indexed citations
11.
Landells, Ian, Colleen Marano, Shu Li, et al.. (2015). Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology. 73(4). 594–603. 166 indexed citations
12.
Feldman, Steven R., Susan D. Mathias, Brad Schenkel, et al.. (2014). Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire. Value in Health. 17(3). A289–A289. 1 indexed citations
13.
Iyer, Shrividya, B. Randazzo, Evan Tzanis, et al.. (2011). Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value in Health. 14(1). 177–183. 36 indexed citations
14.
Michna, Edward, E. Richard Blonsky, Seth L. Schulman, et al.. (2011). Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study. Journal of Pain. 12(5). 554–562. 118 indexed citations
15.
Michna, Edward, Seth L. Schulman, Wenjin Wang, et al.. (2011). Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis. Pain Medicine. 12(8). 1223–1230. 14 indexed citations
16.
Tal‐Singer, Ruth, Rath Pichyangkura, Eugene Chung, et al.. (1999). The Transcriptional Activation Domain of VP16 Is Required for Efficient Infection and Establishment of Latency by HSV-1 in the Murine Peripheral and Central Nervous Systems. Virology. 259(1). 20–33. 36 indexed citations
17.
Kucharczuk, John C., B. Randazzo, Michael Y. Chang, et al.. (1997). Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.. PubMed. 57(3). 466–71. 96 indexed citations
18.
Randazzo, B., John C. Kucharczuk, Leslie A. Litzky, et al.. (1996). Herpes Simplex 1716—an ICP 34.5 Mutant—Is Severely Replication Restricted in Human Skin Xenograftsin Vivo. Virology. 223(2). 392–395. 28 indexed citations
19.
Randazzo, B., et al.. (1988). Expression of functional cell surface -inactivator by U937 cells. Clinical Immunology and Immunopathology. 49(3). 463–477. 3 indexed citations
20.
Godfrey, Henry P., et al.. (1987). Murine Alpha-2-Macroglobulin: Localization on a Subpopulation of Macrophages. Immunobiology. 175(3). 183–194. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carrie Brodmerkel Breakdown of academic impact, for papers by Newman Yeilding Breakdown of academic impact, for papers by Lisa T. Dooley Breakdown of academic impact, for papers by Marieke M.B. Seyger Breakdown of academic impact, for papers by Jörg C. Prinz Breakdown of academic impact, for papers by Edward W. Cowen Breakdown of academic impact, for papers by Mary Ann Mascelli Breakdown of academic impact, for papers by Bernard S. Goffe Breakdown of academic impact, for papers by C. Leonardi Breakdown of academic impact, for papers by Martine Bagot
Rankless by CCL
2026